Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?

L. Vitek, C. Bellarosa, C. Tiribelli,

. 2019 ; 106 (3) : 568-575. [pub] 20190301

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023688

Grantová podpora
NV16-27317A MZ0 CEP - Centrální evidence projektů

Observational epidemiological studies showed that mild hyperbilirubinemia has beneficial effects on the prevention of cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. In mammals, bilirubin plays a major role as a potent antioxidant. Uridine 5'-diphospho-glucuronosyl transferase (UGT)1A1 variants coding for bilirubin UDP-glucuronosyl transferase resulting in mild hyperbilirubinemia (as in Gilbert syndrome (GS)) may confer a strong genetic advantage. Strategies to boost bioavailability of bilirubin or to mimic GS represent an attractive approach to prevent many oxidative stress and inflammation-mediated diseases. Even a tiny, micromolar increase in serum bilirubin concentrations substantially decreases the risk of oxidative stress-mediated diseases. There are several possible ways to achieve this, including lifestyle changes, changes in dietary patterns, regular physical activities, or use of chemical drug or of specific plant products either in the form of regular food items or nutraceuticals. Further basic and experimental research is required to fully uncover this promising therapeutic field.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023688
003      
CZ-PrNML
005      
20201214130834.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cpt.1341 $2 doi
035    __
$a (PubMed)30588615
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity? / $c L. Vitek, C. Bellarosa, C. Tiribelli,
520    9_
$a Observational epidemiological studies showed that mild hyperbilirubinemia has beneficial effects on the prevention of cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. In mammals, bilirubin plays a major role as a potent antioxidant. Uridine 5'-diphospho-glucuronosyl transferase (UGT)1A1 variants coding for bilirubin UDP-glucuronosyl transferase resulting in mild hyperbilirubinemia (as in Gilbert syndrome (GS)) may confer a strong genetic advantage. Strategies to boost bioavailability of bilirubin or to mimic GS represent an attractive approach to prevent many oxidative stress and inflammation-mediated diseases. Even a tiny, micromolar increase in serum bilirubin concentrations substantially decreases the risk of oxidative stress-mediated diseases. There are several possible ways to achieve this, including lifestyle changes, changes in dietary patterns, regular physical activities, or use of chemical drug or of specific plant products either in the form of regular food items or nutraceuticals. Further basic and experimental research is required to fully uncover this promising therapeutic field.
650    _2
$a věkové faktory $7 D000367
650    _2
$a bilirubin $x biosyntéza $7 D001663
650    _2
$a kardiovaskulární nemoci $x prevence a kontrola $7 D002318
650    _2
$a diabetes mellitus 2. typu $x prevence a kontrola $7 D003924
650    _2
$a Gilbertova nemoc $x patofyziologie $7 D005878
650    _2
$a glukuronosyltransferasa $x genetika $7 D014453
650    _2
$a lidé $7 D006801
650    _2
$a hyperbilirubinemie $x epidemiologie $x genetika $x patofyziologie $7 D006932
650    _2
$a mediátory zánětu $x antagonisté a inhibitory $7 D018836
650    _2
$a životní styl $7 D008019
650    _2
$a metabolický syndrom $x prevence a kontrola $7 D024821
650    _2
$a oxidační stres $x fyziologie $7 D018384
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a sexuální faktory $7 D012737
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bellarosa, Cristina $u Fondazione Italiana Fegato ONLUS, AREA Science Park-Basovizza, Trieste, Italy.
700    1_
$a Tiribelli, Claudio $u Fondazione Italiana Fegato ONLUS, AREA Science Park-Basovizza, Trieste, Italy.
773    0_
$w MED00001155 $t Clinical pharmacology and therapeutics $x 1532-6535 $g Roč. 106, č. 3 (2019), s. 568-575
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30588615 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130833 $b ABA008
999    __
$a ok $b bmc $g 1596007 $s 1114364
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 106 $c 3 $d 568-575 $e 20190301 $i 1532-6535 $m Clinical pharmacology & therapeutics $n Clin Pharmacol Ther $x MED00001155
GRA    __
$a NV16-27317A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...